Skip to main content

Month: May 2020

Festi hf.: Breytingar á framkvæmdastjórn

Gréta María Grétarsdóttir hefur óskað eftir að láta af störfum sem framkvæmdastjóri Krónunnar en hún mun starfa áfram þangað til nýr framkvæmdastjóri hefur verið ráðin.„Tími minn hjá Krónunni hefur verið frábær, fyrst sem fjármálastjóri og svo sem framkvæmdastjóri. Það hafa verið forréttindi að fá að vera hluti af eins öflugu liði og Krónuliðið er. Það er gríðarlega erfið ákvörðun að hætta hjá Krónunni en á sama tíma hefur verið lærdómsríkt og krefjandi að leiða félagið í gegnum eigendaskipti og að búa til leiðandi afl á matvörumarkaði. Í mínu starfi hef ég lagt ríka áherslu á að sýna samfélagslega ábyrgð í verki og hafa áherslur okkar í þeim efnum meðal annars gert það að verkum að við höfum markvisst aukið hlutdeild okkar á markaði. Ég er mjög stolt af þeim árangri sem við höfum náð og kveð með söknuði. Ég vil nota tækifærið og þakka...

Continue reading

FTI Consulting’s Jordan Rae Kelly Named to Global Investigations Review’s 40 Under 40 List

WASHINGTON, May 14, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that Jordan Rae Kelly, a Senior Managing Director and Head of Cybersecurity for the Americas at FTI Consulting, has been recognized in the third edition of Global Investigations Review’s 40 Under 40 guide, which honors leading young investigations specialists from across the globe.At FTI Consulting, Ms. Kelly advises clients on a broad range of cybersecurity and data privacy matters involving breaches, insider threats, intellectual property, crisis communications, vendor management, compliance, regulation, risk management and forensic investigations.“It comes as no surprise to me that Global Investigations Review has identified Jordan as a leader in the investigations community,” said Anthony J. Ferrante, Global Head of Cybersecurity at...

Continue reading

Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020

RICHMOND HILL, Ontario, May 14, 2020 (GLOBE NEWSWIRE) — Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer (“LDOS001”) will be published at the ASCO 2020 Annual Conference.The ASCO publication details are:Abstract: e21680Title: Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (“NSCLC”) patients.Authors: Afshin Dowlati, Chandra Prakash Belani, George R. Simon, Heman Chao, Sarina Anne Piha-Paul; University Hospitals Case Medical...

Continue reading

Adaptimmune Reports Q1 Financial Results

– Upfront payment of $50m received from Astellas and approximately $90m offering completed –            – Financial guidance confirmed: funded into 2H 2021 –– Orphan Drug Designation positive opinion for ADP-A2M4 in the EU adds to US FDA ODD and RMAT designations –– Upcoming presentations at major scientific meetings with data from ADP-A2M4, ADP-A2AFP, and allogeneic programs –– Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) –PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 14, 2020 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, reported financial results for the first quarter ended March 31, 2020.“After announcing responses in multiple solid tumors in January, we saw increased momentum across...

Continue reading

CloudMD Welcomes Mark Kohler as Chairman of the Board

VANCOUVER, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (CSE: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company revolutionizing the delivery of healthcare to patients, is pleased to announce its Board of Directors has appointed industry veteran, Mark Kohler as Chairman of the Board.Mr. Kohler has over 33 years of experience as an entrepreneur, investor, financial executive, and board member at leading healthcare, technology, and financial services organizations in North America. With extensive experience as a C-Level financial executive at both private and publicly listed growth organizations, he is best known as a keen supporter of healthcare technology companies, digital health and virtual care adoption while he has also been focused on M&A,...

Continue reading

NexTech Integrates Google Hangouts, Cisco Webex into its InfernoAR Virtual Events platform

NEW YORK and TORONTO, May 14, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, AR learning applications, and virtual events is pleased to announce that it has expanded its infernoAR platform integration with all major platforms including its previously announced integration with Zoom, Microsoft Teams, Skype, and new integrations with Cisco Webex, BlueJeans, Google Hangouts, Google Meet, and GoToMeetings. These critical integrations continue to extend the capabilities of the platform, broaden the utility of the platform and help end-users become even more productive while using the platform.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9f15c422-1fe5-4949-8534-28430fec6b6fUsers...

Continue reading

Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31.A summary is provided below; the full poster will be placed on Surface Oncology’s website following the presentation.Presentation Type: e-poster (Abstract: 3064 / Poster: 128)Title: Results of a first-in-human Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibodyLead Author: Amita PatnaikSession: Developmental Therapeutics – ImmunotherapyIn 2018, Surface Oncology deprioritized...

Continue reading

Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced that holders of its 11.5 million outstanding warrants will have until 5:00 p.m., New York City time, on June 15, 2020 to exercise their warrants.  The 11.5 million warrants are exercisable for an aggregate of 5.75 million shares of Immunovant’s common stock at a price of $11.50 per share, representing a total of $66.125 million in potential proceeds to Immunovant.  Pursuant to the warrant agreement, Immunovant is entitled to redeem all of the outstanding warrants if the last sale price of its common stock is at least $16.50 per share on each of 20 trading days within any 30 trading-day period.  This share price performance target...

Continue reading

Net1 to Host Conference Call to Review Third Quarter 2020 Results

JOHANNESBURG, South Africa, May 14, 2020 (GLOBE NEWSWIRE) — Net 1 UEPS Technologies, Inc. (NasdaqGS: UEPS; JSE: NT1) (“Net1”) today announced it will release third quarter 2020 results after the market close on May 26, 2020. Net1 management will host a conference call to review these results on May 27, 2020, at 8:00 a.m. Eastern Time.To participate in the call, dial 1-508-924-4326 (US and Canada), 0333-300-1418 (U.K. only) or 010-201-6800 (South Africa only) ten minutes prior to the start of the call. Callers should request “Net1 call” upon dial-in. The call will also be webcast on the Net1 homepage, www.net1.com. Please click on the webcast link at least ten minutes prior to the call. A webcast of the call will be available for replay on the Net1 website through June 18, 2020.About Net1 (www.net1.com)Net1 is a multinational financial...

Continue reading

Kommuniké från årsstämma i Corline Biomedical AB (publ)

Idag den 14 maj 2020 hölls årsstämma i Corline Biomedical AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades enhälligt.Fastställande av resultatBolagsstämman fastställde resultat- och balansräkningarna och beslutade, i enlighet med styrelsens förslag, att de disponibla vinstmedlen enligt den fastställda resultaträkningen skulle överföras i ny räkning. Någon utdelning lämnas inte.AnsvarsfrihetBolagsstämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för förvaltningen av Bolagets angelägenheter under räkenskapsåret 2019.Fastställande av antalet styrelseledamöter, styrelsesuppleanter och antalet revisorerStämman beslutade att styrelsen ska bestå av fyra (4) styrelseledamöter samt en (1) styrelsesuppleant. Vidare beslutades att bolaget ska fortsätta ha ett registrerat...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.